ClinicalTrials.gg
CompletedNCT01139047Updated Aug 1, 2022Results posted

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

A Phase 4 interventional study of metronidazole 1% gel and azelaic acid 15% gel in Skin Manifestations, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Skin Manifestations with a site in United States — 2 open to participants now, 3 under way, 2 of them phase 3. Skin Manifestations · United States.

Started
2010
with 3 others
Phase 4
2 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
5 of 10
Galderma R&D

Among the 10 studies in Skin Manifestations with a site in United States, this one is one of 4 that started in 2010, is one of 2 in phase 4, and was the 4th registered.

Skin Manifestations

29 studies on the registry are indexed under Skin Manifestations; 5 are open to participants now.

Browse Skin Manifestations studies →

Open to participants now

2 of the 10 studies in Skin Manifestations with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Skin Manifestations studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Skin Manifestations with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.

03

Conditions studied

  • Skin Manifestations

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female adults (ages 18 years or older)
  • Subjects with healthy skin as determined by the clinical grader

Exclusion criteria

Exclusion Criteria:

  • Subjects with a degree of skin pigmentation that interferes with the reading of skin reactions
  • Subjects with known allergy to one of the components of the study drugs (refer to the package inserts for MetroGel® 1% and Finacea® Gel 15%)
  • Subjects who have participated in another drug or device research study within 30 days of enrollment
  • Subjects with a for topical treatment on the treated area less than 1 week for and/or 4 weeks for retinoids
  • Subjects with a washout period for systemic treatment less than 1 week for medications that may increase photosensitivity and/or 4 weeks for corticosteroids and/or 6 months for retinoids
  • Subjects with current sunburn, eczema, atopic dermatitis, perioral dermatitis, rosacea, or other topical conditions on the area to be treated
  • Subjects who foresee unprotected and intense UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
77 participants (actual)

Study arms

  • Active comparator
    metronidazole 1% gel

    Drug: metronidazole 1% gel

  • Active comparator
    azelaic acid 15% gel

    Drug: azelaic acid 15% gel

Interventions

  • Apply topically once daily on one side of the face for three weeks

    Also known as: MetroGel® 1% gel

  • Apply topically twice daily on the opposite side of the face for three weeks

    Also known as: Finacea® 15% Gel

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3

    Number of participants who were a success with regard to worst post-baseline tolerability scores in each of the tolerability assessments at any time point between baseline and week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0.

    Time frame: baseline to week 3

Secondary outcomes

  1. Number of Participants Who Were a Success With Regard to Worst-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) on Day 22

    Number of participants who were a success with regard to worst-baseline tolerability assessment scores for each assessment (erythema, scaling, dryness, stinging/burning) on day 22. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0 for each assessment.

    Time frame: day 22

  2. 6 Question Subject Preference Survey at Week 3

    Number of participants per response to each question of the subject preference survey at week 3

    Time frame: 3 weeks

07

Results

Posted Jul 26, 2011

Participant flow

Dates of recruitment period: First subject was enrolled on June 7, 2010 and the last subject was enrolled on June 7, 2010.

Participant flow — Overall Study
MilestoneMetroGel® 1% and Finacea® Gel 15%
Started77
Completed76
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3

Number of participants who were a success with regard to worst post-baseline tolerability scores in each of the tolerability assessments at any time point between baseline and week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0.

Time frame:
baseline to week 3
Reported as:
Number · participants
Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3
participantsMetroGel® 1%Finacea Gel® 15%
Erythema1213
Scaling6160
Dryness4848
Stinging/Burning6534
SecondaryNumber of Participants Who Were a Success With Regard to Worst-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) on Day 22

Number of participants who were a success with regard to worst-baseline tolerability assessment scores for each assessment (erythema, scaling, dryness, stinging/burning) on day 22. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0 for each assessment.

Time frame:
day 22
Reported as:
Number · participants
Number of Participants Who Were a Success With Regard to Worst-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) on Day 22
participantsMetroGel® 1%Finacea Gel® 15%
Erythema3333
Scaling6971
Dryness5051
Stinging/Burning7763
Secondary6 Question Subject Preference Survey at Week 3

Number of participants per response to each question of the subject preference survey at week 3

Time frame:
3 weeks
Reported as:
Number · participants
6 Question Subject Preference Survey at Week 3
participantsMetroGel® 1% and Finacea Gel® 15%
1. Side of face felt better MetroGel®21
1. Side of face felt better Finacea®14
1. Side of face both felt same30
1. Side of face neither felt better12
1. Side of face felt better Missing0
2. Overall impression of MetroGel® Very pleasant3
2. Overall impression of MetroGel® Pleasant36
2. Overall impression of MetroGel® Okay34
2. Overall impression of MetroGel® Unpleasant4
2. Overall impression of MetroGel® Very unpleasant0
2. Overall impression of MetroGel® Missing0
3. Overall impression of Finacea® Very pleasant5
3. Overall impression of Finacea® Pleasant26
3. Overall impression of Finacea® Okay38
3. Overall impression of Finacea® Unpleasant5
3. Overall impression of Finacea® Very unpleasant3
3. Overall impression of Finacea® Missing0
4. Side of face more sensitive MetroGel®4
4. Side of face more sensitive Finacea®32
4. Side of face more sensitive both felt same12
4. Side of face more sensitive Neither29
4. Side of face more sensitive Missing0
5. Which side was easier to use MetroGel®?13
5. Which side was easier to use Finacea®?13
5. Which side was easier to use both equal?50
5. Which side was easier to use Neither?1
5. Which side was easier to use Missing0
6. Which product tell a friend about MetroGel®?13
6. Which product tell a friend about Finacea®?11
6. Which product tell a friend about Both?32
6. Which product tell a friend about Neither?21
6. Which product tell a friend about Missing?0

Adverse events

Collected over 3 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MetroGel® 1%—0/77 (0%)0/77 (0%)
Finacea® Gel 15%—0/77 (0%)6/77 (7.8%)
Most frequent other events
Most frequent other events
EventMetroGel® 1%Finacea® Gel 15%
application site pruritusGeneral disorders0/776/77

Baseline characteristics

Age, Continuous
Age, Continuous(years)MetroGel® 1% and Finacea® Gel 15%
Mean42.4 ± 15.07
Sex: Female, Male
Sex: Female, Male(Participants)MetroGel® 1% and Finacea® Gel 15%
Female61
Male16
08

Study locations

1 site
  • Thomas J. Stephens & Associates, Inc.
    Colorado Springs, Colorado 80915, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2010
First posted
Jun 8, 2010
Start
Jun 2010
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results first posted
Jul 26, 2011
Last update
Aug 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01139047
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 8, 2010
Start date
Jun 2010
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Jul 26, 2011
Last update
Aug 1, 2022

Study contacts

Ronald W Gottschalk, MD
study director · Galderma R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metronidazole · Azelaic acid

Start the discussion